

Joon Oh Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/718793/publications.pdf>

Version: 2024-02-01

227
papers

10,469
citations

71102

41
h-index

38395

95
g-index

233
all docs

233
docs citations

233
times ranked

14840
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 122-132.	2.6	9
2	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2427-2435.	2.5	5
3	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discovery, 2022, 12, 402-415.	9.4	119
4	Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. Gastroenterology, 2022, 162, 509-520.e7.	1.3	23
5	A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology. Molecular Cancer, 2022, 21, 9.	19.2	2
6	Randomized phase II study of nalcap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. Journal of Clinical Oncology, 2022, 40, TPS621-TPS621.	1.6	0
7	Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations.. Journal of Clinical Oncology, 2022, 40, 430-430.	1.6	8
8	Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, TPS632-TPS632.	1.6	2
9	Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. European Journal of Cancer, 2022, 163, 119-127.	2.8	12
10	HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology, 2022, 12, 834104.	2.8	6
11	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. Journal of Oncology, 2022, 2022, 1-9.	1.3	7
12	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , 1.	1.5	1
13	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , .	1.5	0
14	Update of systemic chemotherapy & immunotherapy for bile duct cancers. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S35-S35.	0.1	0
15	Abstract 3389: An exosomal miRNA-based liquid biopsy signature for the noninvasive early detection of pancreatic ductal adenocarcinoma. Cancer Research, 2022, 82, 3389-3389.	0.9	0
16	Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study. Journal of Clinical Oncology, 2022, 40, 3623-3632.	1.6	3
17	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557.	1.6	0
18	Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, e16299-e16299.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66
20	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 365-372.	1.9	6
21	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021, 12, 460-466.	2.5	4
22	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 412-412.	1.6	1
23	Diagnostic model for pancreatic cancer using a multi-biomarker panel. <i>Annals of Surgical Treatment and Research</i> , 2021, 100, 144.	1.0	7
24	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). <i>Journal of Clinical Oncology</i> , 2021, 39, 1108-1118.	1.6	67
25	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	7.0	54
26	Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4164-TPS4164.	1.6	1
27	Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study. <i>European Journal of Cancer</i> , 2021, 155, 97-105.	2.8	5
28	Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154848.	3.4	16
29	Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). <i>European Journal of Cancer</i> , 2021, 157, 31-39.	2.8	5
30	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. <i>In Vivo</i> , 2021, 35, 499-505.	1.3	1
31	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	3.2	20
32	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	3.2	10
33	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110623.	1.9	11
34	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. <i>Targeted Oncology</i> , 2020, 15, 67-73.	3.6	1
35	Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. <i>Genome Medicine</i> , 2020, 12, 80.	8.2	134
36	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	1.6	233

#	ARTICLE	IF	CITATIONS
37	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	3.2	9
38	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1059-1067.	4.1	2
39	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	3.2	8
40	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 3367-3374.	1.0	26
41	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152820.	2.3	6
42	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	7
43	Inhibition of TGF- β 2 signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. <i>Scientific Reports</i> , 2020, 10, 2935.	3.3	18
44	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	8.2	20
45	Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1442-1454.	1.6	52
46	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020, 15, 185-192.	3.6	5
47	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	30.7	297
48	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. <i>Cancer Science</i> , 2020, 111, 513-527.	3.9	32
49	Phase III AFACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region. <i>Journal of Clinical Oncology</i> , 2020, 38, 4515-4515.	1.6	11
50	Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA). <i>Journal of Clinical Oncology</i> , 2020, 38, 637-637.	1.6	16
51	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648.	1.6	3
52	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020, 16, 1069-1081.	2.4	15
53	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or \geq POLE-Mutated Metastatic or Unresectable Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1135-1144.	3.0	43
54	NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS602-TPS602.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).. Journal of Clinical Oncology, 2020, 38, 4624-4624.	1.6	0
56	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. Journal of Clinical Oncology, 2020, 38, e16800-e16800.	1.6	0
57	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. Journal of Clinical Oncology, 2020, 38, 686-686.	1.6	0
58	A clinical scoring system for survival prediction in advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 436-436.	1.6	0
59	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. Journal of Clinical Oncology, 2020, 38, 104-104.	1.6	0
60	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. Journal of Clinical Oncology, 2020, 38, 750-750.	1.6	1
61	Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. Cancer Research and Treatment, 2020, 52, 446-454.	3.0	5
62	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. OncoTargets and Therapy, 2019, Volume 12, 225-231.	2.0	4
63	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. Journal of Cancer, 2019, 10, 3140-3144.	2.5	5
64	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discovery, 2019, 9, 1388-1405.	9.4	155
65	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (â‰¥45 Years) With Gastric Cancer. Anticancer Research, 2019, 39, 5811-5820.	1.1	6
66	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 3111-3123.	1.6	100
67	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Scientific Reports, 2019, 9, 15365.	3.3	54
68	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. Translational Oncology, 2019, 12, 1488-1495.	3.7	6
69	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987112.	3.2	27
70	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Annals of Oncology, 2019, 30, 1959-1968.	1.2	37
71	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Translational Oncology, 2019, 12, 597-601.	3.7	8
72	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. PLoS ONE, 2019, 14, e0215080.	2.5	2

#	ARTICLE	IF	CITATIONS
73	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	2.5	7
74	Bridging genomics and phenomics of gastric carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2407-2417.	5.1	40
75	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. <i>Frontiers in Oncology</i> , 2019, 9, 1327.	2.8	5
76	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , 2019, 10, 6185-6190.	2.5	7
77	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. <i>Scientific Reports</i> , 2019, 9, 19439.	3.3	8
78	TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). <i>European Journal of Cancer</i> , 2019, 106, 78-88.	2.8	21
79	Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy. <i>Surgery</i> , 2019, 165, 579-585.	1.9	25
80	Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer. <i>Annals of Surgery</i> , 2019, 269, 678-685.	4.2	37
81	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3104-3104.	1.6	2
82	Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4117-4117.	1.6	63
83	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β 2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4124-4124.	1.6	24
84	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4-LBA4.	1.6	11
85	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 1128-1134.	3.0	12
86	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019, 51, 876-885.	3.0	8
87	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 344-344.	1.6	1
88	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 213-213.	1.6	0
89	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. <i>Translational Cancer Research</i> , 2019, 8, 2107-2112.	1.0	0
90	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4508-4515.	0.0	4

#	ARTICLE	IF	CITATIONS
91	Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2018, 268, 215-222.	4.2	497
92	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. <i>ESMO Open</i> , 2018, 3, e000326.	4.5	52
93	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 140-146.	2.3	17
94	Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. <i>Annals of Oncology</i> , 2018, 29, 1037-1048.	1.2	85
95	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 155-e17.	3.7	21
96	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, 165-169.	2.3	71
97	Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 206-214.	2.3	14
98	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018, 11, 353-357.	3.7	8
99	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018, 18, 1103.	2.6	25
100	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018, 18, 348.	2.5	12
101	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	21.4	145
102	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018, 9, 3394-3399.	2.5	5
103	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018, 9, 1791-1796.	2.5	7
104	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 306-312.	0.6	12
105	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	30.7	1,071
106	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018, 9, 2910-2915.	2.5	6
107	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , 2018, 119, 19-26.	6.4	28
108	Prognostic Role of Carcinoembryonic Antigen Level after Preoperative Chemoradiotherapy in Patients with Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1772-1778.	1.7	7

#	ARTICLE	IF	CITATIONS
109	Geographic and ethnic heterogeneity in the <i>BRCA1/2</i> pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology, 2018, 36, 4115-4115.	1.6	15
110	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. Journal of Clinical Oncology, 2018, 36, e14501-e14501.	1.6	1
111	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	1.6	0
112	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	1.6	0
113	Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis. Cancer Research and Treatment, 2018, 50, 791-800.	3.0	6
114	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Journal of Geriatric Oncology, 2017, 8, 170-175.	1.0	39
115	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Investigational New Drugs, 2017, 35, 782-790.	2.6	22
116	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer, 2017, 17, 211.	2.6	24
117	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer, 2017, 81, 17-25.	2.8	64
118	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. Oncoimmunology, 2017, 6, e1356150.	4.6	32
119	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. Oncologist, 2017, 22, 1169-1177.	3.7	14
120	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. Molecular and Clinical Oncology, 2017, 7, 27-31.	1.0	15
121	Disappearing or residual tiny (4mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?. European Radiology, 2017, 27, 3088-3096.	4.5	20
122	<i>HER2</i> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Molecular Cancer Therapeutics, 2017, 16, 228-238.	4.1	38
123	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2017, 3, 235.	7.1	74
124	Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer. Tumori, 2017, 103, 345-352.	1.1	1
125	Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Oncotarget, 2017, 8, 93117-93130.	1.8	28
126	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). Journal of Cancer, 2017, 8, 1395-1399.	2.5	20

#	ARTICLE	IF	CITATIONS
127	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2017, 8, 2809-2815.	2.5	18
128	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. <i>Journal of Cancer</i> , 2017, 8, 2713-2719.	2.5	16
129	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA as Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	3.0	31
130	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 11094-11104.	1.8	21
131	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	1.8	68
132	TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4099-4099.	1.6	2
133	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15610-e15610.	1.6	1
134	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	1.8	20
135	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. <i>Oncotarget</i> , 2017, 8, 42478-42486.	1.8	32
136	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017, 8, 73974-73980.	1.8	5
137	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017, 8, 105727-105734.	1.8	16
138	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	1.8	23
139	Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. <i>Radiation Oncology Journal</i> , 2017, 35, 217-226.	1.5	5
140	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. <i>Cancer Research and Treatment</i> , 2017, 49, 350-357.	3.0	23
141	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14622-e14622.	1.6	0
142	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15686-e15686.	1.6	0
143	VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4024-4024.	1.6	1
144	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016, 7, 1044-1048.	2.5	17

#	ARTICLE	IF	CITATIONS
145	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 2173-2178.	2.5	1
146	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	3.0	19
147	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016, 16, 105.	2.5	34
148	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016, 7, 43492-43503.	1.8	45
149	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 979-985.	2.3	30
150	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. <i>Translational Oncology</i> , 2016, 9, 173-178.	3.7	22
151	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. <i>BMC Cancer</i> , 2016, 16, 120.	2.6	35
152	A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 1206-1214.	6.4	47
153	Clinical Significance of Mucinous Rectal Adenocarcinoma following Preoperative Chemoradiotherapy and Curative Surgery. <i>Tumori</i> , 2016, 102, 114-121.	1.1	9
154	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	2.5	11
155	Intratumoral heterogeneity of 18F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1461-1468.	6.4	90
156	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet</i> , 2016, 387, 545-557.	13.7	878
157	An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.. <i>Journal of Clinical Oncology</i> , 2016, 34, 642-642.	1.6	1
158	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. <i>Oncotarget</i> , 2016, 7, 62676-62686.	1.8	6
159	Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. <i>Oncotarget</i> , 2016, 7, 75482-75491.	1.8	18
160	Integrated genomic analyses identify frequent gene fusion events and <i>VHL</i> inactivation in gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016, 7, 6538-6551.	1.8	29
161	Integrated genomic approaches identify upregulation of <i>SCRN1</i> as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. <i>Oncotarget</i> , 2016, 7, 13797-13809.	1.8	7
162	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. <i>Oncotarget</i> , 2016, 7, 19610-19619.	1.8	12

#	ARTICLE	IF	CITATIONS
163	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 24088-24096.	1.8	15
164	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016, 34, 34-44.	1.5	10
165	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 153-161.	3.0	11
166	Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 1274-1285.	3.0	14
167	Adjuvant chemotherapy with or without concurrent radiotherapy in stage IB patients with gastric cancer: Subgroup analysis of the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 95-95.	1.6	0
168	The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 302-302.	1.6	0
169	Association of ECOG performance status with efficacy in patients receiving panitumumab with best supportive care (BSC) vs BSC alone for chemorefractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, e15018-e15018.	1.6	0
170	Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2016, 34, 3536-3536.	1.6	0
171	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution. <i>Journal of Clinical Oncology</i> , 2016, 34, 4091-4091.	1.6	0
172	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation. <i>Journal of Clinical Oncology</i> , 2016, 34, e15153-e15153.	1.6	0
173	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015, 8, 288-294.	3.7	8
174	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015, 15, 747.	2.6	10
175	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015, 6, 40360-40369.	1.8	85
176	Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis. <i>Yonsei Medical Journal</i> , 2015, 56, 82.	2.2	5
177	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	1.8	25
178	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	1.8	57
179	Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2015, 47, 343-361.	3.0	75
180	Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 256-260.	1.3	20

#	ARTICLE	IF	CITATIONS
181	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015, 8, 40-46.	3.7	16
182	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 3130-3136.	1.6	370
183	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 859-870.	10.7	699
184	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015, 15, 530.	2.6	17
185	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3858-3865.	1.6	248
186	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiation Oncology</i> , 2015, 117, 171-177.	0.6	31
187	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2522-2522.	1.6	2
188	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4077-4077.	1.6	3
189	Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398). <i>Journal of Clinical Oncology</i> , 2015, 33, 2522-2522.	1.6	1
190	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α -fetoprotein (AFP) from the randomized phase III REACH study. <i>Journal of Clinical Oncology</i> , 2015, 33, 232-232.	1.6	14
191	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015, 6, 24320-24332.	1.8	32
192	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	1.8	48
193	The NEXT-1 (Next generation personalized TX with multi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	1.8	24
194	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , 2015, 6, 40026-40035.	1.8	15
195	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035.	1.8	53
196	Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?. <i>Radiation Oncology Journal</i> , 2015, 33, 83.	1.5	6
197	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx). <i>Journal of Clinical Oncology</i> , 2015, 33, 133-133.	1.6	0
198	Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program. <i>Journal of Clinical Oncology</i> , 2015, 33, 175-175.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4049-4049.	1.6	2
200	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3576-3576.	1.6	3
201	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.. Journal of Clinical Oncology, 2015, 33, 4108-4108.	1.6	0
202	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	1.6	0
203	Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach. Journal of Gastric Cancer, 2014, 14, 87.	2.5	163
204	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification. Molecular Cancer Therapeutics, 2014, 13, 2527-2536.	4.1	34
205	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nature Communications, 2014, 5, 5477.	12.8	166
206	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2014, 15, 1245-1253.	10.7	336
207	Simvastatin plus capecitabine+cisplatin versus placebo plus capecitabine+cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. European Journal of Cancer, 2014, 50, 2822-2830.	2.8	79
208	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 2014, 50, 2072-2081.	2.8	283
209	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Scientific Reports, 2014, 4, 7592.	3.3	24
210	Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status. PLoS ONE, 2014, 9, e103551.	2.5	21
211	Prognostic and predictive value of liver volume in colorectal cancer patients with unresectable liver metastases. Radiation Oncology Journal, 2014, 32, 77.	1.5	3
212	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 447-56.	1.4	25
213	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. Journal of Clinical Oncology, 2014, 32, 4008-4008.	1.6	1
214	Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genomics and Proteomics, 2014, 11, 259-66.	2.0	25
215	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. Anticancer Research, 2014, 34, 6585-91.	1.1	2
216	Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer. PLoS ONE, 2013, 8, e82770.	2.5	36

#	ARTICLE	IF	CITATIONS
217	Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology, 2013, 31, 3608-3608.	1.6	3
218	Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.. Journal of Clinical Oncology, 2013, 31, 4013-4013.	1.6	27
219	Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.. Journal of Clinical Oncology, 2013, 31, 4021-4021.	1.6	24
220	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial. Journal of Clinical Oncology, 2012, 30, 268-273.	1.6	667
221	Profiling of activated receptor tyrosine kinases in advanced gastric cancers identifies patients with poor prognosis.. Journal of Clinical Oncology, 2012, 30, 4011-4011.	1.6	8
222	Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 5233-5239.	1.6	175
223	Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. Current Therapeutic Research, 2007, 68, 193-204.	1.2	1
224	Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria. Japanese Journal of Clinical Oncology, 2003, 33, 533-537.	1.3	195
225	Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research and Treatment, 1998, 49, 41-50.	2.5	15
226	Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Medical Journal, 1998, 39, 27.	2.2	23
227	Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 1970, 47, 72-77.	3.0	20